ORGANIZATION

• Mitsubishi Tanabe’s Ueno Elected as New JPMA President
  May 26, 2023

• Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
  May 24, 2023

• Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
  May 19, 2023

• Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
  May 15, 2023

• Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
  May 10, 2023

• JPMA Nudges Govt to Take Special Measures for Infectious Disease Biz
  May 9, 2023

• JPWA Urges Govt to Take Steps against Drug Shortages Based on Overseas Examples
  May 9, 2023

• Trade Group Demands Better Market Environment for Regenerative Medicine, Proposes New Pricing Model
  April 28, 2023

• Health Care Science Institute Proposes Policies for Solving Distribution Issues, Reviewing Pricing System
  April 26, 2023

• Just Protecting Prices of On-Patent Meds Would Lead to 1.3% Growth in Japan: PhRMA
  April 24, 2023

• Asian Pharma Groups Adopt Position Paper to Push E-Labeling
  April 20, 2023

• Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
  April 17, 2023

• Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
  April 17, 2023

• European Pharma CEOs Prod Japan to Rethink Drug Pricing System: Forum
  April 13, 2023

• Scrap Numerical Target for Generic Use: Gx/Biosimilar Association to Govt
  April 11, 2023

• Generic Use Rate Hits Record 81.2% in October-December: JGA
  April 7, 2023

• JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
  March 30, 2023

• JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
  March 29, 2023

• Six Wholesalers Barred from NHO Bids after FTC Confirms Bid-Rigging
  March 28, 2023

• Hight Time to Hold Fundamental Debate on Drug Price Revisions: FPMAJ Director General
  March 24, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• …
• Next ›
• 最終 »